Funder: Breakthrough T1D
Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full Proposal)
Funding Amounts: Up to $3,000,000 total for up to 3 years; maximum 10% indirect costs (SRA mechanism)
Summary: Supports clinical trials to advance therapies for cardiovascular disease in individuals with type 1 diabetes.
Key Information: LOI required; industry and academic applicants eligible; drug supply and site feasibility must be secured prior to funding.